- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04369625
Children of Mentally Ill Parents-Network - CHIMPS-NET (CHIMPS-NET)
Cross-sector Care for Children and Adolescents With Mentally Ill and Addicted Parents - Children of Mentally Ill Parents -Network - CHIMPS-NET
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The central objectives of the study at hand are the implementation, evaluation and transfer of three evidence-based innovative forms of care (CHIMPS-Therapy, CHIMPS-MFT-Group, CHIMPS-Prevention-Single) for children and adolescents (aged 3 to 18 years) with mentally ill parents at the 19 participating study cites in 12 federal states of Germany. In addition, iCHIMPS, an online intervention based on the CHIMPS concept for the whole family, will be developed.
The four innovative forms of care include diagnostic, prevention and - if needed - therapy in order to treat psychological symptoms of children and adolescents as early as possible. Thereby, chronification will be prevented and the cycle of transgenerational transmissions of psychiatric disorders will be broken. Each of the four interventions will be evaluated in a separate prospective, randomized-controlled trial (RCT); overall, four randomized-controlled trials will be performed. Each of the four control groups receives treatment as usual (TAU). Each of the four studies will include two groups: one intervention group (IG) and one control group (KG), i.e. CHIMPS-T vs. KG (TAU), CHIMPS-MFT-group vs. KG (TAU), CHIMPs-P vs. KG (TAU), iCHIMPS vs. KG (TAU). Central psychosocial outcomes will be assessed at four time points (t1, t2, t3, t4) at baseline as well as after six, 12 and 18 months. Due to a longer development period, iCHIMPS will have three times of measurement over a period of nine months (baseline, post-intervention after 2 months as well as six-months-followup) within the project term. Outcomes will be assessed from the perspectives of the mentally ill parent, the partner (if available), every child and adolescent (0 - 9 years only external assessment; from 10 years of age additional self-assessment) and the professionals. A special characteristic of the study at hand is the comprehensive accompanying evaluation of medical biometry, health economics and qualitative evaluation.
In addition, various sub-projects for systematic implementation will be conducted:
optimization of pathway to care, knowledge and skills of professionals, development of a screening instrument and external quality assurance. In order to evaluate the effect of these three implementation strategies, an implementation study with a cluster-randomized trial was designed. Nineteen clinical centers are taking part in the implementation study. Nine of the nineteen clinical centers will receive the support of one of the three implementation strategies, the other ten clinical centers make up the control group and do not get a specific implementation support. The allocation is randomized. With three questionnaires in the investigator's implementation study we want to identify factors hindering or promoting implementation processes.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Silke Wiegand-Grefe, Prof. Dr.
- Phone Number: . 0049-40-7410-53603
- Email: swiegand-grefe@uke.de
Study Contact Backup
- Name: Anna Leidger, M. Sc.
- Phone Number: +49 40 7410 52633
- Email: a.leidger@uke.de
Study Locations
-
-
-
Hamburg, Germany, 20246
- Recruiting
- University Medical Center Universitätsklinikum Hamburg-Eppendorf, Klinik für Kinder- und Jugendmedizin
-
Contact:
- Silke Wiegand-Grefe, Prof. Dr.
- Phone Number: 0049-40-7410-53603
- Email: silke.wiegand-grefe@uke.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Familiy with at least one psychiatrically ill parent (all F-diagnoses in ICD-10) and at least one child between the age of 3 and 18 years.
- Consent to participate in the study.
- Sufficient knowledge of the German language of parents and children.
- Consent to data processing of the insurance companies, if insured with one of the participating insurance companies.
- Consent to participation in special care (in case of interventions).
Exclusion Criteria:
Severe psychiatric disorders and impairments of parents or children with acute symptoms such as suicidal tendencies, severe depression, addictions, acute psychotic symptoms etc., which will not be sufficiently supplied by these new lowfrequency interventions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CHIMPS-T
(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee.
The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
|
CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
|
Experimental: CHIMPS-P
CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening.
These families will receive the 3 family sessions from the modular CHIMPS intervention.
The sessions will be carried out by a social worker (based on the Finnish model "Let's talk about children (Solantaus), but in a family setting "Let's talk WITH children").
|
CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening.
These families will receive the 3 family sessions from the modular CHIMPS intervention.
|
Experimental: The CHIMPS-MFT-group
The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach.
The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
|
The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach.
The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
|
Experimental: iCHIMPS
iCHIMPS is an online intervention.
In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group.
iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
Overall, 8 consecutive online modules as well as elective modules will be included.
These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents.
iCHIMPS will be completed by 2 booster session within a six months follow-up.
|
iCHIMPS is an online intervention.
In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group.
iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
|
No Intervention: Treatment as usual
The treatment as usual implies that families of the control group receive the treatment that is customary in regular care.
Thus, these families normally don't receive any post-treatment.
If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Children's and adolescent's psychiatric symptomatology (CBCL)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Children's and adolescent's psychiatric symptomatology, assessed from the perspective of the parents by the Child Behaviour Checklist (CBCL 1,5-5; Achenbach & Rescorla, 2000), (CBCL 6-18R; Döpfner, Pflück, Kinnen, & Arbeitsgruppe Deutsche Child Behavior Checklist, 2014).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sociodemographic information
Time Frame: At baseline of the study]
|
Sociodemographic information of the parents, assessed from the perspective of the parents.
|
At baseline of the study]
|
Psychiatric disorders of the children and adolescents (YSR)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Psychiatric disorders of the children and adolescents, assessed from the perspective of the parents by the "Youth Self Report" (YSR; Döpfner, Pflück, Kinnen & Arbeitsgruppe Deutsche Child Behavior Checklist, 2014).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Psychiatric disorders of the children and adolescents (K-SADS-PL)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Psychiatric disorders of the children and adolescents, assessed from the perspective of an external rater by the Kiddie-SADS (K-SADS-PL) (Delmo, Weiffenbach, Gabriel, Stadler & Poustka, 2001).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Psychiatric symptomatology of the children and adolescents (GAF)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Psychiatric symptomatology of the children and adolescents, assessed from the perspective of an external rater by the "Global Assessment of Functioning" (GAF; Saß, Wittchen, Zaudig & Houben, 2003).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents (BSI)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents, assessed from the perspective of the parents by the "Brief Symptom Inventory" (BSI; Franke, 2000).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents (PHQ)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents, Mental health of the parents, assessed from the perspective of the parents by the "Patient Health Questionnaire" (PHQ; PHQ; Löwe, Spitzer, Zipfel & Herzog, 2002).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents (GAF)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Mental health of the parents, assessed from the perspective of an external rater by the "Global Assessment of Functioning" (GAF; Saß, Wittchen, Zaudig & Houben, 2003).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
General anxiety of the parents (GAD-7)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
General anxiety of the parents, assessed from the perspective of the parents by the "Gerneralized Anxiety Disorder-7" (GAD-7; Kroenke, Spitzer, Williams, Monahan, & Löwe, 2007).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the parents (SF-12)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the parents, assessed from the perspective of the parents by the "Short Form 12" (SF-12; Bullinger & Kirchberger, 1998)
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the parents (EQ-5D)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the parents, assessed from the perspective of the parents by the EQ-5D (EQ-5D; Brooks, Rabin & Charro, 2003; Hinz, Klaiberg, Brahler & Konig, 2006).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the children and adolescents (KIDSCREEN)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Health-related quality of life of the children and adolescents, assessed from the perspective of the child/adolescent (from 10 years of age) and from the perspective of the parents by the Kidscreen-27 (The KIDSCREEN Group Europe, 2006).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family functioning (GARF)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family functioning, assessed from the perspective of an external rater by the "Global Assessment of Relational Functioning" (GARF; Saß, Wittchen, Zaudig & Houben, 2003).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family functioning (FB-A)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family functioning, assessed from the perspective of the parents and the children and adolescents (from 10 years of age) by the "Allgemeiner Familienfragebogen" (FB-A; Cierpka & Frevert, 1995)
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Social support of the parents (OSSQ)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Social support of the parents, of the children and adolescents, assessed from the perspective of the parents, of the children and adolescents (from 10 years of age) by the "Oslo Social Support Questionnaire" (OSSQ; Dalgard, 2006).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Parental stress coping (EBI)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Parental stress coping, assessed from the perspective of the parents by the "Elterliches Belastungsinventar" (EBI; Tröster, 2010).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Treatment evaluation (FBB)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Treatment evaluation, assessed from the perspective of the parents, the children and adolescents (from 10 years of age) as well as from the therapist by the "Fragebogen zur Behandlungsbeurteilung" (FBB; Mattejat & Remschmidt, 1999).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Satisfaction with the treatment (ZUF-8)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Satisfaction with the treatment of the parents, of the children and adolescents, assessed from the perspective of the parents and from the perspective of the children/adolescents (from 10 years of age) by the "ZUF-8" (Schmidt, Lamprecht & Wittmann, 1989).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Therapeutic activity and therapeutic processes (VPPS)
Time Frame: During the intervention
|
Therapeutic activity and therapeutic processes, assessed from the perspective of the therapist by the "Vergleichende Psychotherapy Prozess Skalen" (VPPS; Beutel et al., 2016).
|
During the intervention
|
Treatment costs (CAMHSRI-DE)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Treatment costs of the children and adolescents, assessed from the perspective of an external rater by the German version of the "Children and adolescent mental health services receipt inventory" (CAMHSRI-DE; Kilian, Losert, McDaid, Park, Knapp, Beecham, Kusakovskaja, Murauskiene & the CAMHEE Project, 2009).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Treatment costs (CSSRI-DE)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Treatment costs of the parents, assessed from the perspective of an external rater by the German version of the "Client Socioeconomic and Services Receipt Inventory" (CSSRI-DE; Roick, Kilian, Matschinger, Bernert, Mory & Angermeyer, 2001).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family-oriented attitude (FFMHPQ)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Family-oriented attitude, assessed from the clinical employee's point of view by the German version of the "Family Focused Mental Health Practice Questionnaire" (FFMHPQ, Laser et al., 2019).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Implementation components (ICQ)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Implementation components, assessed from the clinical employee's point of view by the German version of the "Implementation Components Questionnaire" (ICQ, Laser, Skogøy, Maybery & Wiegand-Grefe, 2019).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Implementation Satisfaction (ISS)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
|
Implementation Satisfaction, assessed from the clinical employee's point of view by the German version of the "Implementation Satisfaction Scale" (ISS, Laser, Skogøy, Maybery & Wiegand-Grefe, 2019).
|
Change from baseline of the study at 6,12 and 18 months after the randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- U1111-1244-6111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Health Issue
-
King's College LondonCompletedMental Health Wellness 1 | Mental Health IssueUnited Kingdom
-
Hospices Civils de LyonNot yet recruiting
-
The Hong Kong Polytechnic UniversityRecruiting
-
Stanford UniversityNot yet recruitingMental Health Issue
-
The Hong Kong Polytechnic UniversityRecruiting
-
Weill Medical College of Cornell UniversityDoris Duke Charitable FoundationNot yet recruiting
-
Yale UniversityEmpowerment to Heal - Uganda; Empower Through HealthRecruiting
-
The Hong Kong Polytechnic UniversityRecruiting
-
Dr. Nazanin AlaviWithdrawnMental Health IssueCanada
-
Northwestern UniversityWithdrawnMental Health IssueUnited States
Clinical Trials on CHIMPS-T
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; University of Ulm; Universitätsklinikum... and other collaboratorsCompletedSubstance-Related Disorders | Personality Disorders | Mood Disorders | Neurotic Disorders | Schizophrenia and Disorders With Psychotic FeaturesGermany, Switzerland
-
Biotronik SE & Co. KGCompletedHeart Failure | BradycardiaDenmark, Hong Kong, Austria, Germany, Belgium
-
University of California, BerkeleyUniversity of Nevada, Reno; World Bank; L'Office National de Nutrition, MadagascarRecruitingEarly Childhood DevelopmentMadagascar
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular TachycardiaGermany, Czech Republic
-
University of South FloridaNational Cancer Institute (NCI)RecruitingCancer | Obesity, Childhood | SurvivorshipUnited States
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
The First Affiliated Hospital of Soochow UniversityRecruitingRelapsed/Refractory B-cell Non-Hodgkin's LymphomaChina
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States
-
Sorrento Therapeutics, Inc.WithdrawnBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic AntigenUnited States